Stockscreener 앱 받기
0.3946
2.97%
0.0114
시장 영업 전:
.39
-0.0046
-1.17%
전일 마감가:
$0.3832
열려 있는:
$0.3943
하루 거래량:
9.82M
Relative Volume:
0.69
시가총액:
$4.28M
수익:
$9.81M
순이익/손실:
$-26.16M
주가수익비율:
-0.0102
EPS:
-38.77
순현금흐름:
$-17.45M
1주 성능:
+3.84%
1개월 성능:
-40.57%
6개월 성능:
-93.37%
1년 성능:
-95.92%
1일 변동 폭
$0.37
$0.436
1주일 범위
$0.3016
$0.4925
52주 변동 폭
$0.30
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
명칭
Reshape Lifesciences Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
RSLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
0.3946 | 4.28M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Reshape Lifesciences Inc 주식(RSLS)의 최신 뉴스
Insider Sale Alert: ReShape Lifesciences Inc [RSLS] – Is it Time to sell? - knoxdaily.com
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System - MSN
ReShape Shares Soar After USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences secures patent for diabetes treatment By Investing.com - Investing.com South Africa
ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences (RSLS) Gains on Diabetes Neuromodulation Patent News - GuruFocus
ReShape Lifesciences secures patent for diabetes treatment - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for - GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - Yahoo
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Why Did ReShape Lifesciences Plunge 11.04%? Earnings Miss, Bearish Sentiment - AInvest
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop - Investing.com UK
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates - TipRanks
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
ReShape Lifesciences Shares Surge 82.2% After Partnership Announcement - AInvest
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
US Stocks Likely To Open Lower Ahead Of March Inflation Release: Expert Highlights 'Fairly Weak Returns' After 5%+ Gains In S&P 500 - Benzinga
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Benzinga
ReShape secures exclusive deal for neuromuscular rehab tech By Investing.com - Investing.com South Africa
ReShape Lifesciences to Bring Motion Informatics' Neuromuscular Rehabilitation Devices to US - MarketScreener
ReShape secures exclusive deal for neuromuscular rehab tech - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market - The Manila Times
ReShape Lifesciences® Partners with Motion Informatics to - GlobeNewswire
AI Breakthrough: ReShape Brings Next-Gen Neuro Rehabilitation Platform to US Healthcare - Stock Titan
RSLS stock touches 52-week low at $0.34 amid market challenges - Investing.com India
ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - MarketScreener
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - GlobeNewswire
ReShape Lifesciences Inc. SEC 10-K Report - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
ReShape Lifesciences shareholders approve key proposals By Investing.com - Investing.com Australia
Nasdaq Tumbles 100 Points; UniFirst Posts Upbeat Earnings - Benzinga
Pre-market Movers: IBG, JYD, SBFM, SPWH, RSLS… - RTTNews
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
ReShape Lifesciences shareholders approve key proposals - Investing.com
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket - Benzinga
Stock Market News For Apr 2, 2025 - Yahoo Finance
ReShape Lifesciences Delays Yearly Report Filing - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Power Nickel (TSX.V: PNPN) – Undervalued Precious, Battery, Energy and Base Metals Play Amidst Gold Surge – More Stocks Inside - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Global Bariatric Surgeries Market to Hit USD 27.64 Billion - GlobeNewswire
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Finance
Nueva Network Launches Que-Onnda Radio in Washington DC & Boston - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Frazier Life Sciences Welcomes Chris Aakre as Principal of Company Creation - Yahoo Finance
Reshape Lifesciences Inc (RSLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
자본화:
|
볼륨(24시간):